Estela Rodriguez, Associate Director of Community Outreach for Thoracic Oncology and Co-Lead of the Thoracic Site Disease Group at Sylvester Comprehensive Cancer Center, shared on X:
“Melanoma research lead the way in the approval of checkpoint inhibitors. Excited to see this Merck and Moderna press release about the positive pivotal Phase 3 INTerpath-001 trial in resected stage IIB–IV melanoma, RFS were significantly improved vs pembrolizumab alone. ~1,100 patients.
This is precision immuno-oncology at the individual neoantigen patient level.
Now the big question:
Can we reproduce this across lung, bladder, and other solid tumors? “
Quoting Merck:
“In collaboration with Moderna, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely resected stage IIB-IV”
You can also read:Melanoma Research Foundation Highlights New CURE OM Report
